Opening doors in pharmaceutical development

Evidera surveys the adoption of machine learning by the pharmaceutical industry and looks at how it can increase R&D efficiencies.

Despite the advances in the adoption of ML methods in the pharmaceutical industry, there is room for increased application, especially in late stage development.

According to a 2017 survey of 3,073 companies globally from 14 business sectors, only 16% of health care firms adopted at least one artificial intelligence (AI) technology, compared to many other industries over 20%.

• Read the article in full in pharmaphorum’s Deep Dive digital magazine